Generated by AI
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases. ADMA’s current portfolio includes FDA-approved immune globulin and hyperimmune products used to help treat primary humoral immunodeficiency, support immune-compromised patients, and provide protection in hepatitis B exposure settings. The company operates an integrated model that combines plasma collection, fractionation, purification, and commercialization, allowing it to support the supply of its therapies through its own manufacturing infrastructure. ADMA serves healthcare providers and patients in the United States and internationally, with a business centered on plasma-derived therapeutics and targeted immunology applications. Headquartered in Ramsey, New Jersey, ADMA Biologics plays a specialized role in the plasma medicines market by supplying niche biologic treatments for clinical use.
Website465 State Route 17
Ramsey, NJ, 07446
United States
The latest articles about ADMA.
Tipranks Press Release.
Summary of Nov 16's posts. Generated by AI.
Summary of May 7's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Summary of Apr 29's posts. Generated by AI.
Investors talking about ADMA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.